Monthly Archives: May 2012

Vertex pharmaceutical executives cash in on false hopes

Share Senior executives at Vertex Pharmaceuticals made millions of dollars each by selling company stock in the days after the Cambridge-based pharmaceutical reported promising clinical trial data on an experimental drug for cystic fibrosis. And then weeks after they cashed … Continue reading

Posted in biotech industry, clinical trials, conflicts of interest, drug marketing, pharmaceutical industry, Uncategorized | Tagged , , , , , | 4 Comments

Fast-moving bill in Congress would weaken FDA oversight of new drugs and devices

Share Congress is moving quickly to pass a bill that would authorize higher industry fees for the FDA in exchange for speeding up the approval of some drugs and medical devices and eliminating restrictions on financial conflicts of interest among … Continue reading

Posted in clinical trials, conflicts of interest, drug marketing, FDA, medical devices, pharmaceutical industry, public health | Tagged , , , , , | 1 Comment

Institute of Medicine report concludes that the FDA is not doing adequate job of assessing drug benefits and risks

Share Two weeks ago, I headlined my blog with this question: Is the FDA violating its own mandate to approve safe drugs? Four days later, the national Institute of Medicine (IOM) released a 233-page report concluding that FDA’s current approach … Continue reading

Posted in antidepressants, clinical trials, drug marketing, FDA, media coverage, National Institutes of Health, patient care, pharmaceutical industry, Uncategorized | Tagged , , , , , , , | 1 Comment